New Anti-Cancer Niraparib Tosylate Monohydrate Powder CAS 1038915-60-4

China New Anti-Cancer Niraparib Tosylate Monohydrate Powder CAS 1038915-60-4, Find details about China 1038915-60-4, CAS 1038915-60-4 from New Anti-Cancer Niraparib Tosylate Monohydrate Powder CAS 1038915-60-4

Basic Info.

Model NO.

1038915-60-4

Storage Condition

Store at Rt

Trademark

Fousi

Transport Package

Aluminium Foil Bag

Specification

Origin

China

Model NO.

1038915-60-4

Storage Condition

Store at Rt

Trademark

Fousi

Transport Package

Aluminium Foil Bag

Specification

Origin

China

Product Desciption

New Anti-Cancer Niraparib Tosylate Monohydrate Powder
CAS 1038915-60-4

Product Introduction:
Niraparib is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer.
The drug is approved by the US FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

Product Name	Niraparib
CAS No.	1038915-60-4
Purity	99%
Grade Standard	Veterinary Drug Standard
MF	C19H20N4O
MW	320.39
Test Method	HPLC
Other Name	Niraparib Powder
Appearance	White Powder
Brand	MT

Applications:
Niraparib is a small molecule inhibitor of poly ADP-ribose polymerase that is used in the therapy of selected patients with refractory and advanced ovarian carcinoma.
Niraparib therapy is associated with a low rate of transient elevations in serum aminotransferase during therapy, but has not been linked to instances of clinically apparent liver injury.

New Anti-Cancer Niraparib Tosylate Monohydrate Powder CAS 1038915-60-4